Abstract
Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science
Volume: 8 Issue: 3
Author(s): Elaine O. Petrof
Affiliation:
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Abstract: Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Export Options
About this article
Cite this article as:
Petrof O. Elaine, Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151977
DOI https://dx.doi.org/10.2174/187152309789151977 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Latest Therapeutic Novelties and Patents in Pulmonary Hypertension
Recent Patents on Cardiovascular Drug Discovery Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism COVID-19 Related Coagulopathy: What is Known Up to Now
Current Medicinal Chemistry Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Prescription Opioid Abuse and its Potential Role in Gross Dental Decay
Current Drug Safety Commentary (Research Highlights: WNT-erizing Against Neuropathic Pain)
CNS & Neurological Disorders - Drug Targets N-Terminal Microdomain Peptide from Human Dihydroorotate Dehydrogenase: Structure and Model Membrane Interactions
Protein & Peptide Letters Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Concepts for Biologically Active Peptides
Current Pharmaceutical Design Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide
Current Alzheimer Research Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances
Reviews on Recent Clinical Trials The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design The Importance of Some Plant Extracts as Skin Anti-aging Resources: A Review
Current Pharmaceutical Biotechnology Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action
Current Hypertension Reviews Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Role of Bactericidal/Permeability-Increasing Protein (BPI) in Sepsis and Liver Cirrhosis, and Its Clinical Implications
Anti-Infective Agents Interferon-α / β-Receptor Interactions: A Complex Story Unfolding
Current Pharmaceutical Design Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets